

Robin E Ferner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8985502/publications.pdf>

Version: 2024-02-01

76
papers

1,983
citations

331538

21
h-index

265120

42
g-index

85
all docs

85
docs citations

85
times ranked

2785
citing authors

#	ARTICLE	IF	CITATIONS
1	Chloroquine and hydroxychloroquine in covid-19. <i>BMJ, The</i> , 2020, 369, m1432.	3.0	297
2	Clarification of Terminology in Drug Safety. <i>Drug Safety</i> , 2005, 28, 851-870.	1.4	221
3	Clarification of Terminology in Medication Errors. <i>Drug Safety</i> , 2006, 29, 1011-1022.	1.4	207
4	The pathophysiology of medication errors: how and where they arise. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 605-613.	1.1	99
5	Remdesivir in covid-19. <i>BMJ, The</i> , 2020, 369, m1610.	3.0	91
6	Preventability of Drug-Related Harms – Part I. <i>Drug Safety</i> , 2010, 33, 985-994.	1.4	61
7	Unlicensed and off-label uses of medicines: definitions and clarification of terminology. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2615-2625.	1.1	55
8	Patient Experiences of Serious Adverse Drug Reactions and Their Attitudes to Medicines. <i>Drug Safety</i> , 2011, 34, 319-328.	1.4	52
9	A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 566-577.	1.1	52
10	The epidemiology of medication errors: the methodological difficulties. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 614-620.	1.1	51
11	Medication errors: problems and recommendations from a consensus meeting. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 592-598.	1.1	47
12	Medical Devices: Definition, Classification, and Regulatory Implications. <i>Drug Safety</i> , 2020, 43, 83-93.	1.4	47
13	Deaths from Medicines: A Systematic Analysis of Coroners' Reports to Prevent Future Deaths. <i>Drug Safety</i> , 2018, 41, 103-110.	1.4	42
14	Internet Accounts of Serious Adverse Drug Reactions. <i>Drug Safety</i> , 2012, 35, 1159-1170.	1.4	37
15	Ethnic Differences in the Risks of Adverse Reactions to Drugs Used in the Treatment of Psychoses and Depression. <i>Drug Safety</i> , 2008, 31, 597-607.	1.4	35
16	EIDOS. <i>Drug Safety</i> , 2010, 33, 15-23.	1.4	35
17	Preventability of Drug-Related Harms – Part II. <i>Drug Safety</i> , 2010, 33, 995-1002.	1.4	34
18	A systematic review of the evidence for acute tolerance to alcohol – the ‘Mellanby effect’. <i>Clinical Toxicology</i> , 2017, 55, 545-556.	0.8	34

#	ARTICLE	IF	CITATIONS
19	Monitoring drug treatment. <i>BMJ: British Medical Journal</i> , 2003, 327, 1179-1181.	2.4	27
20	Susceptibility to adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2205-2212.	1.1	24
21	Over the counter medicines: proceed with caution. <i>BMJ: British Medical Journal</i> , 2008, 336, 694-696.	2.4	22
22	Dose Omissions in Hospitalized Patients in a UK Hospital. <i>Drug Safety</i> , 2012, 35, 677-683.	1.4	22
23	The problem of orphan drugs. <i>BMJ: British Medical Journal</i> , 2010, 341, c6456-c6456.	2.4	22
24	Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 52-55.	1.1	21
25	Can an electronic prescribing system detect doctors who are more likely to make a serious prescribing error?. <i>Journal of the Royal Society of Medicine</i> , 2011, 104, 208-218.	1.1	19
26	The law of mass action and the pharmacological concentrationâ€“effect curve: resolving the paradox of apparently nonâ€“doseâ€“related adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 56-61.	1.1	19
27	Preventing Future Deaths from Medicines: Responses to Coronersâ€™ Concerns in England and Wales. <i>Drug Safety</i> , 2019, 42, 445-451.	1.4	19
28	Deaths attributed to the use of medications purchased online. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 60-64.	1.7	18
29	A Strategy for Regulatory Action When New Adverse Effects of a Licensed Product Emerge. <i>Drug Safety</i> , 2009, 32, 91-98.	1.4	17
30	The toxicological significance of post-mortem drug concentrations in bile. <i>Clinical Toxicology</i> , 2018, 56, 7-14.	0.8	17
31	Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 109-117.	1.1	15
32	Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity. <i>Drug Safety</i> , 2022, 45, 137-144.	1.4	15
33	A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy. <i>Journal of the Royal Society of Medicine</i> , 2013, 106, 87-119.	1.1	14
34	Adverse drug reactions. <i>BMJ: British Medical Journal</i> , 2018, 363, k4051.	2.4	14
35	An agenda for UK clinical pharmacology: Medication errors. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 912-916.	1.1	12
36	Perceptions and Impact of Mandatory eLearning for Foundation Trainee Doctors: A Qualitative Evaluation. <i>PLoS ONE</i> , 2016, 11, e0168558.	1.1	11

#	ARTICLE	IF	CITATIONS
37	How similar are biosimilars?. BMJ, The, 2016, 353, i2721.	3.0	11
38	An Algorithm for Integrating Contraindications into Electronic Prescribing Decision Support. Drug Safety, 2010, 33, 1089-1096.	1.4	10
39	Biochemical Monitoring of Patients Treated with Antihypertensive Therapy for Adverse Drug Reactions. Drug Safety, 2011, 34, 1049-1059.	1.4	10
40	Medical manslaughter. BMJ, The, 2013, 347, f5609-f5609.	3.0	10
41	Temporal and other factors that influence the time doctors take to prescribe using an electronic prescribing system. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 206-212.	2.2	10
42	Prescribing biosimilars. BMJ: British Medical Journal, 2018, 362, k3141.	2.4	10
43	Tramadol: repeated prescriptions and repeated warnings. BMJ Evidence-Based Medicine, 2021, 26, e17-e17.	1.7	9
44	Harms from medicines: inevitable, in error or intentional. British Journal of Clinical Pharmacology, 2014, 77, 403-409.	1.1	8
45	Overprescribing and rational therapeutics: Barriers to change and opportunities to improve. British Journal of Clinical Pharmacology, 2021, 87, 34-38.	1.1	8
46	Deriving Dose Limits for Warnings in Electronic Prescribing Systems. Drug Safety, 2012, 35, 291-298.	1.4	7
47	Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50. British Journal of Clinical Pharmacology, 2019, 85, 2218-2227.	1.1	7
48	A novel approach to support implementation of biosimilars within a UK tertiary hospital. British Journal of Clinical Pharmacology, 2020, 86, 23-28.	1.1	7
49	Nominal ISOMERs (Incorrect Spellings Of Medicines Eluding Researchers)â€™ variants in the spellings of drug names in PubMed: a database review. BMJ, The, 2016, 355, i4854.	3.0	6
50	Establishing a service to tackle problematic polypharmacy. Future Healthcare Journal, 2020, 7, 208-211.	0.6	6
51	Mefloquine for malarial prophylaxis in military personnel. BMJ, The, 2015, 351, h5797.	3.0	5
52	The relationship between antemortem and postmortem morphine concentrations. Clinical Toxicology, 2019, 57, 1142-1145.	0.8	5
53	Phenytoin and damage to the cerebellum â€™ a systematic review of published cases. Expert Opinion on Drug Safety, 2022, 21, 957-977.	1.0	4
54	Raising more antibodies. BMJ, The, 2013, 347, f5969-f5969.	3.0	2

#	ARTICLE	IF	CITATIONS
55	Medical Devices: Classification and Analysis of Faults Leading to Harms. <i>Drug Safety</i> , 2020, 43, 95-102.	1.4	2
56	Are high-cost drug funding mechanisms fit for purpose? A retrospective study of individual funding requests in an NHS tertiary hospital. <i>British Journal of Clinical Pharmacology</i> , 2020, , .	1.1	2
57	Susceptibilities. <i>BMJ, The</i> , 2012, 345, e6420-e6420.	3.0	1
58	Antithrombotic dose: Some observations from published clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2194-2197.	1.1	1
59	Free-of-charge medicine schemes in the NHS: A local and regional drug and therapeutic committee's experience. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2571-2580.	1.1	1
60	Coping with COVID: preparing prescribers during the pandemic. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	1
61	Prescribing direct-acting oral anticoagulants " Mind the evidence gap. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	1
62	A short history of pharmaceutical marketing. <i>BMJ, The</i> , 2012, 345, e7801-e7801.	3.0	0
63	Interactions. <i>BMJ: British Medical Journal</i> , 2012, 344, e865-e865.	2.4	0
64	Consequences. <i>BMJ, The</i> , 2012, 344, e2859-e2859.	3.0	0
65	Summertime. <i>BMJ, The</i> , 2012, 344, e4245-e4245.	3.0	0
66	Boundaries. <i>BMJ: British Medical Journal</i> , 2012, 344, e2028-e2028.	2.4	0
67	Piquancy. <i>BMJ, The</i> , 2013, 346, f2938-f2938.	3.0	0
68	A fat chance of slimming. <i>BMJ, The</i> , 2013, 347, f7389-f7389.	3.0	0
69	Hallucination. <i>BMJ, The</i> , 2013, 347, f4570-f4570.	3.0	0
70	A bee in the bonnet about honey and healing. <i>BMJ, The</i> , 2013, 347, f5015-f5015.	3.0	0
71	Divination. <i>BMJ, The</i> , 2013, 346, f1536-f1536.	3.0	0
72	Beneath the surface. <i>BMJ, The</i> , 2013, 346, f380-f380.	3.0	0

#	ARTICLE	IF	CITATIONS
73	Authorsâ€™ reply to Green and colleagues. BMJ, The, 2015, 351, h6588.	3.0	0
74	Manslaughter trials ignore systemic failures. BMJ, The, 2016, 355, i6630.	3.0	0
75	Twenty years of adverse drug reactions: a look back â€” part 1. Adverse Drug Reaction Bulletin, 2018, 309, 1195-1198.	0.6	0
76	Twenty years of adverse drug reactions: a look back â€” part 2. Adverse Drug Reaction Bulletin, 2018, 310, 1199-1202.	0.6	0